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ABSTRACT
Objectives. Patients with cancer who are treated with chemotherapy report adverse events during their treatment,
which can affect their quality of life and increase the likelihood that their treatment will not be completed. In this
study, patients’ perceptions of the physician-patient relationship and communication about cancer-related issues,
particularly adverse events were examined.
Methods. We surveyed 508 patients with cancer concerning the occurrence of adverse events and their relationship
and communication with their physicians regarding cancer, treatment, and adverse events.
Results. Most individuals surveyed (>90%) discussed diagnosis, treatment plan, goals, and schedule, and potential
adverse events with their physicians before initiating chemotherapy; approximately 75% of these individuals under-
stood these topics completely or very well. Physician-patient discussions of adverse events were common, with
tiredness, nausea and vomiting, and loss of appetite discussed prior to chemotherapy in over 80% of communica-
tions. These events were also the most often experienced (ranging in 95% to 64% of the respondents) along with low
white blood cell counts (WBCs), which were experienced in 67% of respondents. Approximately 75% of the
individuals reported that their overall quality of life was affected by adverse events.
Conclusions. These ﬁndings suggest that discussions alone do not provide patients with sufﬁcient understanding of
the events, nor do they appear to adequately equip patients to cope with them. Therefore, efforts to improve cancer
care should focus on developing tools to improve patients’ understanding of the toxicities of chemotherapy, as well
as providing resources to reduce the effects of adverse events.
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M
ost patients who are treated with stan-
dardchemotherapyregimensreportadverse
events—including fatigue, nausea, diarrhea, and
pain—during treatment [1,2], but the incidence of
chemotherapy-related adverse events and their
effect on doctors and nurses have been underesti-
mated. A community study in 12,239 women with
breastcancerthatwasconductedin2006foundthat
serious chemotherapy-related adverse events were
more common than had been reported in large
clinical trials and led to more healthcare expendi-
tures than had been estimated [3].
The occurrence of adverse events increases the
likelihood that patients will not complete their
treatment [4–7]. Febrile neutropenia, for example,
is not directly linked to survival but can lead to
life-threatening infections [8,9] and chemotherapy
dose reductions and delays, which can compromise
survival [10–13]. Furthermore, quality of life may
be compromised in patients with cancer who have
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Arch Drug Info 2008;1:70–78 © 2008, Archives of Drug Informationchemotherapy-induced neutropenia [14], fatigue
or anemia [15–17], nausea or vomiting [18,19], or
weight loss [20].
Research in physician-patient communication
has shown that effective communication and active
patient participation in making decisions about
treatments can inﬂuence a patient’s satisfaction,
quality of life, and treatment outcome [21–26]. In
particular, verbal and nonverbal communication
between physicians and patients can affect a
patient’s satisfaction [27,28], adherence [29], and
quality of life [30,31]. Insufﬁcient communication
or miscommunication may compromise a patient’s
ability to participate in making decisions about
treatment [21].
This study examines patients’ perceptions of the
physician-patient relationship and communication
about cancer-related issues, particularly adverse
events. We also performed an exploratory assess-
ment of differences in race concerning patients’
perceptions about physician-patient communi-
cation about cancer-related topics and patients’
understanding of these topics.
Methods
Patients
Individuals surveyed were recruited from Decem-
ber 2003 through January 2004 from the Harris
Interactive Chronic Illness Panel and from
NexCura and were invited to participate in a
secure Internet survey of their opinions on health-
related issues. Participants were invited to com-
plete the online survey if they met the following
criteria: (i) age 18 years; (ii) had been treated for
cancer within the past 12 months; and (iii) had a
diagnosis of lung, breast, colon, pancreatic, or
ovarian cancer, lymphoma (Hodgkin’s or non-
Hodgkin’s), multiple myeloma, or sarcoma.
The Harris Interactive Chronic Illness Panel
consists of more than 2 million US persons who
have been screened for chronic illnesses from the
Harris Interactive general panel of more than 5
million US persons. The cancer subpanel was used
as the primary sample source for all survey respon-
dents. NexCura provides a variety of healthcare
information and communications services, includ-
ing online education for patients, and maintains
a database of more than 500,000 persons with
various illnesses, including cancer.
The participants were given different compen-
sation, according to the source of recruitment.
Patients recruited from the Harris Interactive
Chronic Illness Panel were compensated with 100
HIpoints, the currency of incentive with which
Harris Interactive compensates participants in its
surveys. There is no direct conversion between
HIpoints and US currency, but 800 HIpoints,
for example, can be redeemed for a $5 gift certiﬁ-
cate at retail stores. Patients recruited through
NexCura were paid $25. The study did not collect
protected private health information and was IRB
exempt.
Survey
Participants completed an Internet survey that
required approximately 20 minutes to complete.
The survey questions were obtained from Harris
Poll’s question bank and were customized to the
cancer experience. They addressed patients’ expe-
riences with cancer treatment. Speciﬁcally, discus-
sions about treatment and adverse events were
posed (e.g., Before you started chemotherapy, did
you and your doctor or nurse discuss any of the
following: treatment expectations, possibility of
delays, potential side effects, etc?). Patient under-
standing of the information was asked (e.g., How
well would you say you understand each of
the following: prognosis, treatment expectations,
potential side effects, etc, as well as adverse events
that had occurred?). Questions concerning pa-
tients’ perceptions of their communication and
relationship with their physician were also asked.
For example, the following question was asked:
Overall, how would you rate your relationship
with your doctor? All survey questions are avail-
able on request from the authors.
Statistical Analysis
Final data obtained from the respondents were
weighted to match the characteristics of the tar-
geted cancer patient population by using the fol-
lowing parameters: age, gender, race or ethnicity,
education level, geographic region, and household
income.Demographictargetswereestimatedfrom
an internal Harris Interactive national health-
care survey of chronically ill patients, including a
large number of patients with cancer.
Results
Study Participants
Fivehundredeightpersonswererecruitedthrough
an Internet survey to participate in the study. A
total of 28,075 persons were solicited (8075 from
the Harris Interactive Chronic Illness Panel and
20,000 from NexCura). Of the 28,075 persons,
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the survey. Individuals qualiﬁed for this study if
they answered in the afﬁrmative to the initial
screeningquestionsthatincludedtheinclusioncri-
teria. The participants were predominantly white
(87%) and married (71%); other demographic
characteristics, such as age (65 years or older),
education, and income, were more variably distrib-
uted (Table 1). Eighty-two percent of respondents
had been treated with chemotherapy, and 27%
reported that their cancer had recurred after being
in remission.
Patient-physician Communication
More than 90% of respondents reported that they
had had discussions with their physicians about the
most fundamental aspects of cancer treatment
before starting chemotherapy. The topics dis-
cussed included diagnosis, treatment plan, treat-
ment schedule, treatment goals, and adverse
events (Table 2). Slightly fewer individuals (80%
to 90%) reported having discussed prognosis,
expectations of treatment, doses of chemotherapy,
and medications for adverse events (see Table 2).
At least two thirds of respondents reported having
discussed how to educate themselves about cancer
and the possibility and causes of treatment delays
along with the possibility of treatment delays or
reductions due to low WBCs or RBCs. However,
Table 1 Patient demographics
No. (%) of patients
(N = 508)
Sex*
Female 324 (64)
Male 185 (36)
Age, year*
<35 25 (5)
35–49 92 (18)
50–64 139 (27)
65 253 (50)
Ethnicity*
White 444 (87)
Black 32 (6)
Hispanic 14 (3)
Other 9 (2)
Declined to state 10 (2)
Education
High school or less 240 (47)
Some college 151 (30)
College graduate 117 (23)
Annual household income, $*
<35,000 143 (28)
35,000–75,000 113 (22)
>75,000 127 (25)
Declined to state 126 (25)
Household status
Married or living with partner 359 (71)
Single, never married 29 (6)
Divorced, separated, widowed 121 (24)
Overall health*
Excellent or very good 104 (20)
Good 188 (37)
Fair or poor 217 (43)
Cancer recurred after remission 136 (27)
*It is typical for the sum of the rounded weighted frequencies to be off by 1 or
2 from the overall base size for the question (N = 508).
Table 2 Physician-patient discussions and patient understanding of cancer-related topics
Topic
No. (%) of patients (N = 508)
Patients who
discussed topic before
chemotherapy
Patients who understood
topic “completely” or
“very well”
Patients who understood
topic “somewhat”
or “fairly well”
Diagnosis 489 (96) 393 (77) 109 (21)
Treatment plan 485 (95) 343 (68) 157 (31)
Prognosis 428 (84) 341 (67) 131 (26)
Expectations of treatment outcomes 452 (89) 334 (66) 160 (31)
Potential adverse effects of chemotherapy 486 (96) 359 (71) 144 (28)
How to educate oneself about cancer 365 (72) 316 (62) 163 (32)
The possibility of treatment delays 361 (71) 316 (62) 156 (31)
The cause of treatment delays 334 (66) 317 (62) 161 (32)
The medications used to prevent and
manage adverse events
443 (87) 326 (64) 156 (31)
How much chemotherapy to be given 445 (88) 305 (60) 157 (31)
The chemotherapy schedule 488 (96) 384 (76) 108 (21)
The possibility of dose delays or
reductions because of a
low white blood cell count
386 (76) 341 (67) 129 (25)
The possibility of dose delays or
reductions because of a
low red blood cell count
359 (71) 317 (62) 157 (31)
The goals of treatment 472 (93) 363 (71) 129 (25)
The current “gold standard” of treatment 203 (40) 153 (30) 139 (27)
The number of treatment options available 366 (72) 265 (52) 184 (36)
The possibility that infections can cause
treatment delays
408 (80) 330 (65) 163 (32)
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themselves as understanding these topics “com-
pletely” or “very well” was generally lower for each
topic than the proportion who reported having
discussed it (see Table 2). The proportion of black
respondents who reported that they had discussed
these topics with their physicians and understood
them was lower than that of white respondents
(Figure 1). Overall, the majority of the individuals
reported having had good relationships and good
communication with their physicians, with more
than 90% of respondents expressing satisfac-
tion and trust. Moreover, many reported that they
were comfortable with asking their physicians
questions.
Discussion and Experience of Adverse Events
Ninety-six percent of respondents reported that
they had discussed adverse events with their phy-
sicians before starting chemotherapy (see Table 2),
but their responses to a list of common adverse
events showed that some adverse events were
addressed in 75% or fewer of those discussions
(Table 3). Speciﬁcally, serious adverse events such
as fever and chills (69%) and low white blood cell
counts (79%) were discussed less frequently than
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Figure 1 Physician-patient discussions and patient understanding of information on cancer-related topics. (A) Patients who
discussed cancer-related topics with their physician. (B) Patients who understood the information provided.
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Figure 1 Continued.
Table 3 Physician-patient discussions and patient experience of adverse events
Adverse event
No. (%) of patients (N = 508)
Patients who discussed
symptoms of adverse event
before chemotherapy
Patients who discussed
treatments for adverse event
before chemotherapy
Patients in whom
adverse events
occurred
Tiredness, weakness, or exhaustion 462 (91) 386 (76) 484 (95)
Nausea, vomiting 470 (93) 437 (86) 323 (64)
Loss of appetite, changes in taste 422 (83) 334 (66) 376 (74)
Fever (temperature, chills) 352 (69) 320 (63) 233 (46)
Depression or irritability 264 (52) 232 (46) 269 (53)
Low white blood cell count (neutropenia) 399 (79) 355 (70) 342 (67)
Low red blood cell count (anemia) 395 (78) 357 (70) 282 (56)
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weakness (91%). However, it is encouraging to
discover that the proportion of individuals discuss-
ing adverse events were similar to the proportion
of those who also discussed treatment for those
adverse events (Figure 2).
Many respondents also reported the occurrence
of adverse events during treatment (see Table 3).
The frequencies of such events ranged from 95%
for tiredness, weakness, or exhaustion to 46% for
fever (temperature, chills). Interestingly, the fre-
quencies of discussions of adverse events paralleled
the frequencies of the occurrence of these events:
91% of respondents reported that they had dis-
cussed symptoms of fatigue with their physicians,
and 95% reported that they had experienced it;
52% reported that they had discussed symptoms of
depression, and 53% reported that they had expe-
rienced it. This may indicate that patients have
selective memories about discussions with their
physicians before starting chemotherapy or that
the frequency with which physicians discuss
adverse events relates to how frequently those
events typically occur.
Effects of CancerTreatment–related Adverse Events
The majority of respondents with adverse events
said that those events had had negative effects on
their quality of life (75%), ability to enjoy daily
activities (67%), ability to work (66%), ability to
carry out everyday activities (60%), and ability to
get back to a normal life (56%) (Table 4).
The respondents’ experiences with neutropenia
illustrate the discrepancy between physician-
patient communication and patient understand-
ing. For example, 76% of individuals surveyed
reported having discussed with their physicians the
possibility of chemotherapy modiﬁcations because
of neutropenia, but only 68% reported under-
standing this information “completely” or “very
well.” Also, more than 90% of respondents re-
ported chemotherapy dose modiﬁcations during
their treatment, but the possibility of dose delays
and modiﬁcations was discussed before the start of
chemotherapy in only 65% to 70% of cases.
Discussion
Mostrespondentsreportedhavingagoodrelation-
ship and extensive discussions with their physicians
before beginning chemotherapy about not only
basic aspects of their illness and cancer treatments
but also the adverse events that might occur.
However, serious adverse events such as fever and
chills and low white blood cell counts were dis-
cussed less frequently than events such as nausea,
tiredness,andweakness.Moreover,fewerindividu-
als felt that they fully understood the information
theyhadbeengiven.Also,eventhoughthemajority
of respondents reported having discussed many
Figure 2 Physician-patient discus-
sions about cancer- or chemotherapy-
related adverse events. Patients
who recalled a discussion about the
adverse event are shown in black and
patients who recalled a discussion
about supportive care or treatment for
the adverse event are shown in gray.
91%
93%
83%
69%
52%
78%
79%
76%
86%
66%
63%
46%
70%
70%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Tiredness, Weakness, or Exhaustion
Nausea
Appetite and Taste Changes
Fever
Depression or Irritability
Low Red Blood Cell Count
Low White Blood Cell Count
Percent of Patients (%)
Adverse Events Treatments for Adverse Events
Table 4 Effects of adverse events on patients
Effects of adverse event on patient’s
No. (%) of patients*
(N = 497)
†
Quality of life 389 (78)
Enjoyment of daily activities 334 (67)
Ability to work 326 (66)
Ability to carry out everyday activities 297 (60)
Ability to get back to a normal life 278 (56)
Ability to maintain relationships 227 (46)
*It is typical for the sum of the rounded weighted frequencies to be off by 1 or
2 from the overall base size for the question (N = 508).
†Data are from patients in whom at least 1 adverse event occurred.
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discussions alone do not necessarily translate into
patient understanding. Furthermore, the low
frequency of discussions about some of the less-
common adverse events suggests a need for
improvement in communication, as not all respon-
dents who had adverse events had discussed them
withtheirphysiciansbeforestartingchemotherapy.
There remains a need for developing and using
educational resources for patients with cancer.
The disparity between the number of patients who
believe that these programs are important for
recovery (75%) and the low enrollment rate in
them (7%) suggests that much remains to be done
to encourage and facilitate patient involvement in
these valuable resources and to understand the
barriers to patient involvement that exist.
Furthermore, even though the sample size was
insufﬁcient for statistical analysis of the responses
by race, this exploratory assessment suggests that
black patients do not discuss with their physicians
and therefore do not fully understand detailed
topics related to chemotherapy and possibilities
of dose delays and schedules as often as white
patients. Therefore, these factors may lead to a
decrease in quality of life and ultimately survival.
These observations are consistent with the ﬁnd-
ings in previous research reporting that 5-year sur-
vival rates are lower in black patients than in white
patients in all major cancer types [32–36]. Also,
numerous factors have been explored to explain
the lower survival in black patients with cancer, but
the inﬂuence of cancer treatment-related adverse
events has not been well explored. Due to these
exploratory assessments, we believe these issues
merit further evaluation.
The results of this study should be interpreted
in light of several limitations. For example, partici-
pants were recruited from two cohorts of subjects
who are enrolled in Internet-based survey pro-
grams. Our results were weighted to reﬂect the
demographic characteristics of a general survey
population, but selection bias may limit the gen-
eralizability of our results. In addition, this is a
heterogeneous population composed of individu-
als with different cancer types and treatment regi-
mens; thus, not all adverse events may have been
relevant to each individual. The race differences
that we observed appear large, but because of the
small number of black respondents, the results
may not be reliable, so no deﬁnitive conclusions
can be drawn. The study was also limited by the
use of self-reporting. Since the respondents could
have been treated up to 12 months before partici-
pating in the study, the responses may be subject to
recall bias. Furthermore, since data were collected
online and without conﬁrmation by medical
records or reports from physicians, it is possible
that there were individuals who experienced an
adverse event but either were unaware of it or did
not understand the terminology used to describe
it in the survey.
We were reassured to ﬁnd that physician-
patient discussions of adverse events were com-
mon, but it remains a concern that those
discussions alone do not provide patients with
sufﬁcient understanding of the events, nor do
they appear to adequately equip patients to cope
with the adverse events that do occur. Efforts to
improve cancer care should focus on developing
tools to improve patients’ understanding of the
toxicities of chemotherapy, as well as providing
resources to reduce the effects of adverse events.
Acknowledgments
Dr. Hershman is the recipient of a K07 award from the
National Cancer Institute (CA-95597). She is also the
recipient of an ASCO Advanced Clinical Research
Award, and a grant from the American Cancer Society
(RSGT-08-009-01-CPHPS). Amgen provided funding
to support this analysis.
Corresponding Author: Dawn Hershman, MD,
Columbia University Medical Center, Irving Pavilion,
Floor 10, Room 1068, 161 Fort Washington Avenue,
New York, NY 10032, USA. Tel: (212) 305-1945; Fax:
(212) 305-9178; E-mail: dlh23@columbia.edu
Conﬂict of Interest: The study was supported by funding
from Amgen. Dr. Hershman has no conﬂicts. Dr.
Calhoun has no conﬂicts. Dr. Zapert is an employee of
Harris interactive and has stock and stock options in the
company. Dr. Malin was an employee of Amgen during
the analyses of these data and development of this
manuscript and has stock and stock options in the
company. Dr. Barron is an employee of Amgen and has
stock and stock options in the company. Amgen thanks
Anna Maniccia, PhD of MediTech-Media, LTD for
providing medical writing assistance.
References
1 Chang VT, Ingham J. Symptom control. Cancer
Invest 2003;21:564–78.
2 Miller M, Kearney N. Chemotherapy-related
nausea and vomiting—Past reﬂections, present
practice and future management. Eur J Cancer Care
(Engl) 2004;13:71–81.
3 Hassett MJ, O’Malley AJ, Pakes JR, Newhouse JP,
Earle CC. Frequency and cost of chemotherapy-
76 Hershman et al.
Arch Drug Info 2008;1:70–78related serious adverse effects in a population
sample of women with breast cancer. J Natl Cancer
Inst 2006;98:1108–17.
4 Macquart-Moulin G, Viens P, Bouscary ML, Genre
D, Resbeut M, Gravis G, et al. Discordance
between physicians’ estimations and breast cancer
patients’ self-assessment of side-effects of chemo-
therapy: An issue for quality of care. Br J Cancer
1997;76:1640–5.
5 Choi J, Kong K, Mozaffar T, Holcombe RF.
Delayed oxaliplatin-associated neurotoxicity fol-
lowing adjuvant chemotherapy for stage III colon
cancer. Anticancer Drugs 2006;17:103–5.
6 Hillner BE, Schrag D, Sargent DJ, Fuchs CS,
Goldberg RM. Cost-effectiveness projections of
oxaliplatin and infusional ﬂuorouracil versus irino-
tecan and bolus ﬂuorouracil in ﬁrst-line therapy
for metastatic colorectal carcinoma. Cancer
2005;104:1871–84.
7 Chrischilles EA, Link BK, Scott SD, Delgado DJ,
Fridman M. Factors associated with early termina-
tion of CHOP therapy and the impact on survival
among patients with chemosensitive intermediate-
grade non-Hodgkin’s lymphoma. Cancer Control
2003;10:396–403.
8 Dale DC. Colony-stimulating factors for the man-
agement of neutropenia in cancer patients. Drugs
2002;62(suppl ):1–15.
9 Bodey GP, Buckley M, Sathe YS, Freireich EJ.
Quantitative relationships between circulating
leukocytes and infection in patients with acute
leukemia. Ann Intern Med 1966;64:328–40.
10 Dale DC, McCarter GC, Crawford J, Lyman GH.
Myelotoxicity and dose intensity of chemotherapy:
Reporting practices from randomized clinical trials.
J Natl Compr Canc Netw 2003;1:440–54.
11 Lyman GH, Dale DC, Crawford J. Incidence and
predictors of low dose-intensity in adjuvant breast
cancer chemotherapy: A nationwide study of com-
munity practices. J Clin Oncol 2003;21:4524–31.
12 Link BK, Budd GT, Scott S, Dickman E, Paul D,
Lawless G, et al. for the Oncology Practice Pattern
Study Working Group. Delivering adjuvant chemo-
therapy to women with early-stage breast carci-
noma: Current patterns of care. Cancer 2001;92:
1354–67.
13 Bonadonna G, Moliterni A, Zambetti M, Daidone
MG, Pilotti S, Gianni L, et al. 30 years’ follow up of
randomised studies of adjuvant CMF in operable
breast cancer: Cohort study. BMJ 2005;330:217.
14 Fortner BV, Houts AC, Schwartzberg LS. A pro-
spective investigation of chemotherapy-induced
neutropenia and quality of life. J Support Oncol
2006;4:472–8.
15 Littlewood TJ. Efﬁcacy and quality of life outcomes
of epoetin-alpha in a double-blind, placebo-
controlled, multicentre study of cancer patients
receiving non-platinum-containing chemotherapy.
Front Radiat Ther Oncol 2002;37:34–7.
16 Tchekmedyian NS, Kallich J, McDermott A, Fayers
P, Erder MH. The relationship between psycho-
logic distress and cancer-related fatigue. Cancer
2003;98:198–203.
17 Vansteenkiste J, Pirker R, Massuti B, Barata F, Font
A, Fiegl M, et al. Double-blind, placebo-controlled,
randomized phase III trial of darbepoetin alfa in
lung cancer patients receiving chemotherapy. J Natl
Cancer Inst 2002;94:1211–20.
18 Cohen L, de Moor CA, Eisenberg P, Ming EE,
Hu H. Chemotherapy-induced nausea and
vomiting—Incidence and impact on patient quality
of life at community oncology settings. Support
Care Cancer 2007;15:497–503.
19 Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S,
Soru G, et al. The impact of chemotherapy-induced
nausea and vomiting on health-related quality of
life. Support Care Cancer 2007;15:179–85.
20 Jatoi A. Pharmacologic therapy for the cancer
anorexia/weight loss syndrome: A data-driven, prac-
tical approach. J Support Oncol 2006;4:499–502.
21 Jefford M, Tattersall MH. Informing and involving
cancer patients in their own care. Lancet Oncol
2002;3:629–37.
22 Baile WF, Aaron J. Patient-physician communica-
tion in oncology: Past, present, and future. Curr
Opin Oncol 2005;17:331–5.
23 Travaline JM, Ruchinskas R, D’Alonzo GE Jr.
Patient-physician communication: Why and how. J
Am Osteopath Assoc 2005;105:13–8.
24 Smith TJ. Tell it like it is. J Clin Oncol 2003;21
(suppl):12–6.
25 Epstein RM, Alper BS, Quill TE. Communicating
evidence for participatory decision making. JAMA
2004;291:2359–66.
26 Bredart A, Bouleuc C, Dolbeault S. Doctor-patient
communication and satisfaction with care in oncol-
ogy. Curr Opin Oncol 2005;17:351–4.
27 Roter DL, Stewart M, Putnam S, Lipkin M Jr, Stiles
W, Innui TS. Communication patterns of primary
care physicians. JAMA 1997;270:350–6.
28 Liang W, Burnett CB, Rowland JH, Meropol NJ,
Eggert L, Hwang YT, et al. Communication
between physicians and older women with localized
breast cancer: Implications for treatment and
patient satisfaction. J Clin Oncol 2002;20:1008–16.
29 Hall JA, Roter DL, Katz NR. Meta-analysis of cor-
relates of provider behavior in medical encounters.
Med Care 1988;26:657–75.
30 Mandelblatt JS, Kerner JF, Hadley J, Hwang YT,
Eggert L, Johnson LE, et al. Variations in breast
carcinoma treatment in older Medicare beneﬁcia-
ries: Is it black or white. Cancer 2002;95:1401–14.
31 Street RL Jr, Voigt B. Patient participation in decid-
ing breast cancer treatment and subsequent quality
of life. Med Decis Making 1997;17:298–306.
32 Ries LAG, Harkins D, Krapcho M, et al. SEER
cancer statistics review. 1975–2003. Bethesda, MD:
National Cancer Institute. Available at: http://
Patient Perceptions of Adverse Events with Chemotherapy 77
Arch Drug Info 2008;1:70–78www.seer.cancer.gov/csr/1975_2003/ (accessed
December 13, 2006).
33 Shavers VL, Brown ML. Racial and ethnic dispari-
ties in the receipt of cancer treatment. J Natl Cancer
Inst 2002;94:334–57.
34 Grann V, Troxel AB, Zojwalla N, Hershman D,
Glied SA, Jacobson JS. Regional and racial dispari-
ties in breast cancer-speciﬁc mortality. Soc Sci Med
2006;62:337–47.
35 Smigal C, Jemal A, Ward E, Cokkinides V, Smith R,
Howe HL, et al. Trends in breast cancer by race and
ethnicity: Update 2006. CA Cancer J Clin 2006;56:
168–83.
36 Tripathi RT, Heilbrun LK, Jain V, Vaishampayan
UN. Racial disparity in outcomes of a clinical trial
population with metastatic renal cell carcinoma.
Urology 2006;68:296–301.
78 Hershman et al.
Arch Drug Info 2008;1:70–78